1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. Wee1
  4. Wee1 Isoform

Wee1

 

Wee1 Related Products (31):

Cat. No. Product Name Effect Purity
  • HY-10993
    Adavosertib
    Inhibitor 99.96%
    Adavosertib (AZD-1775; MK-1775) is a potent Wee1 inhibitor with an IC50 of 5.2 nM.
  • HY-132295
    Azenosertib
    Inhibitor 99.96%
    Azenosertib (ZN-c3) is a selective, orally active inhibitor for Wee1 inhibitor (IC50=3.9 nM). Azenosertib exhibits antitumor activity.
  • HY-13925
    PD0166285
    Inhibitor 99.46%
    PD0166285, a substrate of P-gp, is a WEE1 inhibitor and a weak Myt1 inhibitor with IC50 values of 24 and 72 nM, respectively. PD0166285 exhibits an IC50 of 3.433 μM for Chk1.
  • HY-147054
    Zedoresertib
    Inhibitor 99.46%
    WEE1-IN-5 is a potent WEE1 inhibitor with an IC50 value of 0.8 nM. WEE1-IN-5 inhibits phospho-CDC2. WEE1-IN-5 abrogates the G2 check point, increasing sensitivity to DNA damaging agents in cancer cells. WEE1-IN-5 can be used for researching anticancer.
  • HY-147312
    GSK-1520489A
    Inhibitor 99.83%
    GSK-1520489A is a PKMYT1 (active protein kinase) inhibitor (IC50=115 nM, Ki=10.94 nM).
  • HY-175749
    BMS-986463
    Degrader
    BMS-986463, a CRBN E3 ligase modulator (CELMoD), is a WEE1 kinase molecular glue degrader. BMS-986463 significantly inhibits tumor regression and reduces the level of phospho-CDK2. BMS-986463 can be used for advanced malignant solid tumors like non-small cell lung cancer (NSCLC) research.
  • HY-178190
    WEE1-IN-13
    Inhibitor
    WEE1-IN-13 (Compound 10) is a highly selective WEE1 kinase inhibitor (IC50=0.7 nM). WEE1-IN-13 abrogates the G2/M checkpoint and induces tumor cell apoptosis. WEE1-IN-13 is promising for research of solid tumors (e.g., non-small cell lung cancer, ovarian cancer).
  • HY-178150
    WEE1-IN-14
    Inhibitor
    WEE1-IN-14 (Compound 14) is a selective WEE1 inhibitor (IC50: 0.5 nM in L-RB-FEP calculations, 1.0 nM in ADP-Glo kinase assay). Inhibition of Wee1 in cancer cells disrupts the G2-M checkpoint, removes the regulatory controls on the cell cycle, and leads to early onset of mitotic failure followed by apoptosis of tumor cells. Therefore, WEE1-IN-14 is a useful tool for studying cancer biology.
  • HY-133618
    Pomalidomide-C3-adavosertib
    Degrader 99.84%
    Pomalidomide-C3-adavosertib is a rapid and selective PROTAC Wee1 degrader (IC50=3.58 nM). Pomalidomide-C3-adavosertib shows anti-cancer cell proliferation activity, and induces apoptosis.
  • HY-108343
    WEE1-IN-4
    Inhibitor 99.70%
    WEE1-IN-4 (Compound 15) is a potent checkpoint Wee1 kinase inhibitor with an IC50 of 0.011 μM. Wee1 inhibitors can abrogate the G2/M checkpoint.
  • HY-103029
    Bosutinib isomer
    Inhibitor 99.62%
    Bosutinib isomer is a ligand or inhibitor with high binding affinity for both Wee1 and Wee2, with Kd values of 43.7 ± 10.0 and 4.7 ± 2.3 nM, respectively.
  • HY-144999
    LEB-03-146
    98.08%
    LEB-03-146 is a WEE1 DUBTAC (deubiquitinase-targeting chimera) linking AZD1775 (Adavosertib) to the OTUB1 recruiter EN523 through a PEG2 linker. LEB-03-146 shows significant WEE1 stabilization in HEP3B hepatoma cancer cells.
  • HY-138239
    WEE1-IN-3
    Inhibitor 98.64%
    WEE1-IN-3 is a potent Wee1 kinase inhibitor with an IC50 of <10 nM. WEE1-IN-3 has anticancer activities.
  • HY-161880
    WEE1-IN-10
    Inhibitor 99.32%
    WEE1-IN-10 (compound 77) is a Wee1 kinase inhibitor. WEE1-IN-10 shows inhibitory activity on LOVO cell growth, with an IC50 of 0.524 μM. WEE1-IN-10 can be used for the research of diseases caused by abnormal activity of Wee1.
  • HY-163697
    WEE1-IN-7
    Inhibitor
    WEE1-IN-7 (compound 12h) is a potent and orally activeWEE1 inhibitor with an IC50 value of 2.1 nM. WEE1-IN-7 induces apoptosis and cell cycle arrest at the S phase. WEE1-IN-7 shows antitumor activity.
  • HY-168654
    WEE1 degrader 1
    Degrader
    WEE1 degrader 1 (Compound 10) is a Wee1 degrader with a DC50 value of 1.5 nM against Wee1. WEE1 degrader 1 possesses anti-cancer cell proliferation effects.
  • HY-10993R
    Adavosertib (Standard)
    Inhibitor
    Adavosertib (Standard) is the analytical standard of Adavosertib. This product is intended for research and analytical applications. Adavosertib (AZD-1775; MK-1775) is a potent Wee1 inhibitor with an IC50 of 5.2 nM.
  • HY-143342
    LEB-03-144
    LEB-03-144 is a WEE1 DUBTAC (deubiquitinase-targeting chimera) linking AZD1775 (Adavosertib) to the OTUB1 recruiter EN523 through a C3 alkyl linker. LEB-03-144 shows significant WEE1 stabilization in HEP3B hepatoma cancer cells.
  • HY-174448
    WEE1-IN-12
    Inhibitor
    WEE1-IN-12 (Compound 87) is a Wee1 kinase inhibitor with an IC50 of 2.0 nM. WEE1-IN-12 can inhibit the proliferation of HT29 cells (IC50: 1.07 μM), and when used in combination with Gemcitabine (HY-17026), the effect is better (IC50: 0.34 μM). WEE1-IN-12 can be used in the research of tumors such as colon cancer.
  • HY-133703A
    i-AZD1775 TFA
    Inhibitor
    i-AZD1775 (TFA) is an immobilizable analogue of AZD1775. i-AZD1775 (TFA) retains the ability to inhibit WEE1 in vitro. i-AZD1775 (TFA) can be studied in anticancer research.